Your nervous system is a key force behind so many important bodily functions. But when your peripheral nerves—those found outside of the brain and spinal cord—are damaged, it can cause pain and ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Management typically involves medications that modify the immune system, but natural treatments may also help reduce symptoms. Lupus is an autoimmune condition. It develops when the immune system ...

David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target is ...

One of the losers of today's trading session was Alnylam Pharmaceuticals. Shares of the Pharmaceutical company plunged -8.7%, ...

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...